Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • Latest News
    • LARC remains highly...

    LARC remains highly effective , Safe contraception method: JAMA

    Written by Medha Baranwal Baranwal Published On 2018-07-12T19:23:03+05:30  |  Updated On 12 July 2018 7:23 PM IST
    LARC remains highly effective , Safe contraception method: JAMA

    In India, about half of the pregnancies are unplanned, according to a study published in the Lancet Global Health. These women are candidates for contraceptive services and counseling. The unplanned pregnancies are associated with increased risks of child and maternal morbidity and add to socioeconomic and mortality burden of the society. Thereby, increasing access to long-acting reversible contraception (LARC) is a critical strategy for decreasing the rate of unplanned pregnancy.


    Related Article: 10 key takeaways from the Lancet study on abortions in India

    LARC includes the subdermal implant and intrauterine devices (IUDs). It is highly efficacious and associated with high rates of continued contraception. Despite a majority of patients being medically eligible for LARC use, it is underutilized (14.3% of all contraceptive use) vs sterilization (28.2%) and hormonal contraception requiring user involvement (31.8%).


    FDA Approved LARC

    The US Food and Drug Administration (FDA) approved contraceptive use includes 1 copper and 4 levonorgestrel-containing IUDs and 1 progestin implant. The progestin implant is placed subdermally with local anesthesia in the upper arm. LARC devices can be inserted and removed by trained professionals (including primary care clinicians) in the office setting without sedation.


    The copper IUD is the most effective method of emergency contraception available (if placed within 5 d of unprotected intercourse; duration, 10-12 y); it inhibits fertilization through spermicidal effect.


    Read Also: ACOG recommends long acting contraception for all adolescents

    LARC provides greater efficacy compared with short-acting hormonal methods that require user involvement. Because LARC requires no user involvement, its effectiveness with typical use (eg, patient adherence) matches its theoretical efficacy with perfect use (>99%). In contrast, the effectiveness of oral contraceptives with typical use is substantially lower (91%) than theoretical efficacy with perfect use (>99%).


    One potential shared disadvantage of LARC is expensive out-of-pocket costs ($500-$1000 for the device plus costs for the office visit and procedure) for patients who lack full contraceptive coverage.


    FDA-Approved Long-acting Reversible Contraception Devices Currently Available in the United States

    Debunking Myths about LARC Safety


    Underutilization of LARC is largely contributed to misunderstandings about its safety. Concerns that women who are nulliparous, unmarried, or adolescents are at higher risk for pelvic inflammatory disease and infertility from using FDA-approved IUDs are not supported by current literature. Any risk of pelvic infection associated with IUD insertion is very low (0.5%) and limited to several weeks postinsertion. IUD users have a lower absolute risk of ectopic pregnancy than non-IUD users, but in the rare event that IUD users become pregnant, the relative risk of ectopic pregnancy is elevated. Patients concerned about devices getting lost should be informed that uterine perforation from IUDs is rare (1/1000 insertions) and distant migration of properly placed subdermal implants is rare (case reports). Upon removal of LARC, baseline fertility rapidly returns. Requirements that LARC only be inserted during menses unnecessarily delay access; LARC can be inserted anytime pregnancy has been reasonably ruled out, based on history and urine pregnancy testing.




    Additional Benefits of LARC


    Noncontraceptive benefits of LARC can improve health outcomes. Levonorgestrel-containing IUDs can treat menstrual-related disorders. By decreasing menses, levonorgestrel-containing IUDs can improve anemia and prevent surgical interventions to treat fibroids and endometriosis. Progestin-containing LARCs can alleviate symptoms related to other menstrual-related conditions, such as dysmenorrhea and migraine headaches. Because progestins suppress endometrial proliferation, the levonorgestrel-containing IUD has been used to treat atypical endometrial hyperplasia.




    Eligibility for LARC Use


    The Centers for Disease Control and Prevention provides evidence-based resources that summarize patient eligibility for different contraceptive methods based on selected patient characteristics and medical conditions. LARC is well suited for patients with medical problems that pose contraindications to estrogen use, including poorly controlled diabetes or hypertension, current or past venous thromboembolism, migraines with aura, and cigarette smokers (aged ≥35 years). All LARC devices can be placed right after birth or abortion, providing immediate contraception. The copper IUD will not interfere with lactogenesis. Multiple randomized clinical trials and observational studies have failed to demonstrate any negative effects of progestin-containing contraceptives (shot, implant, progestin only pills) on the quality of maternal lactation or first-year infant growth.


    For further information follow the link: 10.1001/jama.2018.8877
    contraceptioncontraceptivesimplantsintrauterine devicesIUDsJAMALARClong-acting reversible contraceptionPregnancysubdermal implantsunintended pregnancyunplanned pregnancy
    Source : With inputs from JAMA

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medha Baranwal Baranwal
    Medha Baranwal Baranwal
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok